CSIMarket Company Name, Ticker, Competitors, else..
 
Vaxart Inc   (VXRT)
 
Price: $0.4935 $0.00 0.714%
Day's High: $0.5099999904632568 Week Perf: -3.24 %
Day's Low: $ 0.49 30 Day Perf: -13.42 %
Volume (M): 45,659 52 Wk High: $ 0.84
Volume (M$): $ 0 52 Wk Avg: $0.53
Open: $0.51 52 Wk Low: $0.31



 Market Capitalization (Millions $) 120
 Shares Outstanding (Millions) 242
 Employees 65
 Revenues (TTM) (Millions $) 243
 Net Income (TTM) (Millions $) 39
 Cash Flow (TTM) (Millions $) 31
 Capital Exp. (TTM) (Millions $) 1

Business Description


Vaxart Inc is a biotechnology company that specializes in the development of oral vaccines. They focus on creating vaccines using their proprietary oral tablet vaccine platform instead of the traditional injection-based vaccines. Vaxart's technology allows for the development of vaccines that are easier to administer, more patient-friendly, and potentially more effective. They primarily target infectious diseases, such as the flu, norovirus, and respiratory syncytial virus (RSV), but their platform has the potential to be applied to other diseases as well. The company also collaborates with pharmaceutical partners and government organizations for the development and commercialization of their vaccine candidates.


   Company Address: 310 Utah Avenue, Suite 150 South San Francisco 94080 CA
   Company Phone Number: 550-3500   Stock Exchange / Ticker: VXRT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARMP        8.75% 
ELUT   -6.68%    
IBRX        0.37% 
IVVD   -14.4%    
MRNA        5.48% 
STRO   -1.86%    
• View Complete Report
   



Clinical Study

Navigating Financial Strains Vaxarts Norovirus Vaccine Innovation Illuminates a Positive Path Forward,

Published Thu, Sep 11 2025 3:58 AM UTC

Promising Developments Despite Financial Hurdles: Vaxart’s Advancements in Norovirus Vaccine ResearchIn the complex landscape of pharmaceuticals and vaccine development, financial metrics often cast a long shadow over the innovative strides made by companies. Vaxart Inc, a biotechnology firm known for its diverse pipeline of orally administrable vaccines, is a representa...
Shares

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Thu, Mar 27 2025 12:00 PM UTC

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): A Strategic Move to Attract Talent Amid Market ChallengesSOUTH SAN FRANCISCO, Calif. March 27, 2025 Vaxart, Inc. (Nasdaq: VXRT) announced on March 24, 2025, a strategic initiative aimed at enhancing its workforce by granting inducement equity awards to new employees. This move comes at a critical...
Clinical Study

Vaxarts First-Generation Oral Norovirus Vaccine Shows Promise in Elderly, Yet Shares Lag Behind Market Trends

Published Fri, Mar 7 2025 7:38 AM UTC

Vaxart Inc. has recently announced the publication of an important study showcasing the immunogenicity and safety of its first-generation oral pill Norovirus vaccine candidate, particularly focusing on elderly adults. This development comes at a crucial time, given the heightened vulnerability of this demographic to gastrointestinal infections, including norovirus, which can...
Clinical Study

Advancing COVID-19 Vaccine Development Insights from Vaxarts Phase 2b Clinical Trial

Published Tue, Jan 14 2025 9:42 AM UTC

: This article presents an overview of recent developments in Vaxart s COVID-19 vaccine research, following the favorable review from an Independent Data Safety Monitoring Board (DSMB) regarding the initial safety assessments of its Phase 2b clinical trial. The ongoing search for effective COVID-19 vaccines is critical in the global fight against the pandemic. Vaxart, a biot...
Shares

Vaxart, Inc. Lures Talent with Equity Awards Amidst Share Price Struggles

Published Tue, Nov 19 2024 1:00 PM UTC

In a strategic move to attract top talent, Vaxart, Inc. (Nasdaq: VXRT) announced on November 19, 2024, that its Compensation Committee has granted inducement equity awards, totaling 91,500 shares of common stock. These awards were given to two new non-executive employees, aimed at inducing them to join the ranks of Vaxart. This decision aligns with Nasdaq Listing Rule 5635(c...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 5.48
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.49
Price to Sales (Expected) -
Price to Book 1.45
PEG (TTM) 0.19

Financial Strength Current
Quick Ratio 1.93
Working Capital Ratio 2.68
Leverage Ratio (MRQ) 1.01
Total Debt to Equity -
Interest Coverage (TTM) 24.82
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.09 $
Revenues (TTM) 1 $
Cash Flow (TTM) 0.13 $
Cash 0.58 $
Book Value 0.34 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 3,739,446
Net Income per Employee (TTM) 593,677
Receivable Turnover Ratio (TTM) 15.09
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.18

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -48.45 %
Net Margin (MRQ) -49.64 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 1.07 %

Management Effectiveness Current
Return On Assets (TTM) 18.77 %
Return On Investment (TTM) 46.17 %
Return On Equity (TTM) 53.04 %
Dividend Yield -
Pay out Ratio (TTM) -



Vaxart Inc's Segments
Government Contract    0.19 % of total Revenue
Collaboration Revenue    20.97 % of total Revenue
Single Reportable Segment    244.3 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.